


Complimentary breakfast CE Satellites!

Friday, April 28, 2023



Breakfast & Scientific Session: 7:30 AM – 10:00 AM CT
McCormick Place – South Building
S100 BC, Grand Ballroom



Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

Renowned experts will engage in discussions and debates on the practical implications of sequencing therapeutic agents for mCRPC treatment as well as on the application of new data in clinical situations urologists are likely to encounter in real-world scenarios. The lively discussion will place new developments into clinical context. To be held ancillary to the 2023 AUA Annual Meeting.

LEARNING OBJECTIVES

- Determine the pathophysiology, resistance mechanisms, and diagnostic features that differentiate castration-resistant prostate cancer (CRPC) from hormone-sensitive PC
- Assess recent clinical trial evidence that guides treatment selection in patients with CRPC
- Apply proactive strategies to monitor, recognize, and manage treatment-related adverse events

PROGRAM CHAIR



Judd W. Moul, MD
Distinguished Professor of Urologic Surgery
Duke University School of Medicine
Durham, NC

To register, visit
gotoper.com/AUA_CRPC



Scan with smartphone

Accreditation/Credit Designation

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™.

Acknowledgment of Educational Support

For a full list of educational support please visit gotoper.com/AUA_CRPC.

Breakfast & Scientific Session: 8:00 AM - 10:00 AM CT
McCormick Place Convention Center
Room S106



How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies

This symposium will include discussion of unmet needs for treating NMIBC in the era of BCG shortages and novel treatment strategies including those targeting interleukin-15 (IL-15), white and blue light cystectomy and gene therapy. Expert faculty will discuss the potential these agents confer for expanding the NMIBC treatment armamentarium. Held ancillary to the 2023 AUA Annual Meeting.

LEARNING OBJECTIVES

- Explain the rationale for the development of emerging therapeutic strategies evaluated for the treatment of NMIBC
- Assess recent efficacy and safety data of novel/emerging therapies
- Plan effective strategies for monitoring and mitigating adverse events associated with therapeutic strategies used to treat NMIBC

PROGRAM CHAIR



Ashish M. Kamat, MD, MBBS
Professor, Department of Urology,
Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX

To register, visit
gotoper.com/AUA_NMIBC



Scan with smartphone

Accreditation/Credit Designation

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

Acknowledgment of Educational Support

For a full list of educational support please visit gotoper.com/AUA_NMIBC.

Live attendees must be registered for AUA2023.

